Why is hrt no longer recommended?

Research shows that long-term use of combination hormone therapy (for 5 years or more) increases the risk of breast and ovarian cancer, heart disease, stroke, and lung disease. When started before a woman reaches menopause (during the transition to perimenopause), hormone therapy reduces the risk of this fuel change and can halve a woman's risk of Alzheimer's disease. Once a woman reaches menopause, HRT no longer seems to have this protective effect on the brain. The history of hormone replacement therapy (HRT) began in the 1960s, with a very high popularity in the decade of 1990.

If you are considering taking HRT, the Canadian Cancer Society recommends that you talk to your healthcare provider about how HRT can alleviate menopausal symptoms and about your individual risks. Despite the benefits (such as the reduction of osteoporosis and colon cancer) and the fact that the risk of breast cancer or cardiovascular disease did not increase, the general message about hormone therapy remained negative. When considering the benefits and risks of hormone replacement therapy, concerns about cancer, heart disease, and stroke should be discussed. Based on the purported positive effect of hormone therapy on cardiovascular health, the FDA required that this purported cardiovascular benefit induced by hormone therapy be confirmed by randomized clinical trials.

Cancer and chronic conditions are multifactorial, and modifying a single factor, such as the use of HRT, may not cause a clear epidemiological change. However, the damage persists and a small amount of HRT is still being used around the world, which is unjustified. The negative results of the study received wide publicity, causing panic among some users and new guidelines for doctors about prescribing hormone therapy. Nowadays, the choice to use hormone replacement therapy (HRT) is very personalized and is based on women's needs and potential risk factors, says Dr. The first clinical trials on HRT and chronic postmenopausal conditions began in the U.S.

Department of State in the late 1990s. The enrolled women were randomly assigned to receive hormone replacement therapy (0.625 mg of conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate) or a placebo. It has been suggested that there may be a “window of opportunity”, that is, a period close to menopause when the benefits of hormone therapy outweigh the risks. Combined hormone replacement therapy for menopause is a known cause of breast cancer, especially in women who have recently used or are still using it.

In 1998, the Women's Health Initiative (WHI) was initiated, which was the largest randomized study conducted to date and aimed to evaluate the effect of HRT on the most common causes of death and disability in postmenopausal women, such as cardiovascular disease, cancer and osteoporosis. There is strong evidence that the use of hormonal hormonal therapy increases a woman's risk of getting breast cancer., ovary and uterus.